{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:18:00Z","timestamp":1790983080521,"version":"4.1.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,22]]},"DOI":"10.7759\/cureus.113175","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T22:14:37Z","timestamp":1784758477000},"source":"Crossref","is-referenced-by-count":1,"title":["Atypical Neuroleptic Malignant Syndrome Without Rigidity During Clozapine Titration: A Diagnostic Challenge"],"prefix":"10.7759","author":[{"given":"Kyaw Thiri","family":"Tun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhupawani Wijayasuriya","family":"Wijayasuriya Arachchige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shakeel","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Neuroleptic malignant syndrome. (2024). Accessed. June 19, 2025: https:\/\/bestpractice.bmj.com\/topics\/en-gb\/990."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2016-214901","article-title":"Atypical neuroleptic malignant syndrome","volume":"2016","author":"Collins A","year":"2016","unstructured":"Collins A, Davies D, Menon S. Atypical neuroleptic malignant syndrome. BMJ Case Rep. 2016, 2016:10.1136\/bcr-2016-214901","journal-title":"BMJ Case Rep"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1192\/pb.bp.116.053736","article-title":"Drug information update. Atypical antipsychotics and neuroleptic malignant syndrome: nuances and pragmatics of the association","volume":"41","author":"Sarkar S","year":"2017","unstructured":"Sarkar S, Gupta N. Drug information update. Atypical antipsychotics and neuroleptic malignant syndrome: nuances and pragmatics of the association. BJPsych Bull. 2017, 41:211-6. 10.1192\/pb.bp.116.053736","journal-title":"BJPsych Bull"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.7734","article-title":"The diagnostic dilemma in a patient with neuroleptic malignant syndrome during the COVID-19 pandemic: a significant increase in acute phase reactants","volume":"11","author":"Elyasi F","year":"2023","unstructured":"Elyasi F, Zarghami M, Fariborzifar A, Cheraghmakani H, Shirzad M, Kazempour F. The diagnostic dilemma in a patient with neuroleptic malignant syndrome during the COVID-19 pandemic: a significant increase in acute phase reactants. Clin Case Rep. 2023, 11:e7734. 10.1002\/ccr3.7734","journal-title":"Clin Case Rep"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.142.10.1137","article-title":"Neuroleptic malignant syndrome","volume":"142","author":"Levenson JL","year":"1985","unstructured":"Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry. 1985, 142:1137-45. 10.1176\/ajp.142.10.1137","journal-title":"Am J Psychiatry"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425787","article-title":"Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR)","author":"American Psychiatric Association","year":"2022","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR). American Psychiatric Association, Washington, DC; 2022. 10.1176\/appi.books.9780890425787"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.30773\/pi.2017.06.05","article-title":"A neuroleptic malignant syndrome without rigidity","volume":"15","author":"\u00d6zdemir \u0130","year":"2018","unstructured":"\u00d6zdemir \u0130, Kuru E, Safak Y, Tulac\u0131 RG. A neuroleptic malignant syndrome without rigidity. Psychiatry Investig. 2018, 15:226-9. 10.30773\/pi.2017.06.05","journal-title":"Psychiatry Investig"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S1441-2772(23)01663-0","article-title":"Atypical neuroleptic malignant syndrome with long-term clozapine","volume":"9","author":"Corallo CE","year":"2007","unstructured":"Corallo CE, Ernest D. Atypical neuroleptic malignant syndrome with long-term clozapine. Crit Care Resusc. 2007, 9:338-40. 10.1016\/S1441-2772(23)01663-0","journal-title":"Crit Care Resusc"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200923060-00003","article-title":"Neuroleptic malignant syndrome associated with atypical antipsychotic drugs","volume":"23","author":"Trollor JN","year":"2009","unstructured":"Trollor JN, Chen X, Sachdev PS. Neuroleptic malignant syndrome associated with atypical antipsychotic drugs. CNS Drugs. 2009, 23:477-92. 10.2165\/00023210-200923060-00003","journal-title":"CNS Drugs"},{"key":"ref10","article-title":"Proposed research diagnostic criteria for neuroleptic malignant syndrome","volume":"2","author":"Adityanjee","year":"1999","unstructured":"Adityanjee, Mathews T, Aderibigbe YA. Proposed research diagnostic criteria for neuroleptic malignant syndrome. Int J Neuropsychopharmacol. 1999, 2:129-44.","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-014-0078-0","article-title":"Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis","volume":"15","author":"Belvederi Murri M","year":"2015","unstructured":"Belvederi Murri M, Guaglianone A, Bugliani M, et al.. Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis. Drugs R D. 2015, 15:45-62. 10.1007\/s40268-014-0078-0","journal-title":"Drugs R D"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1159\/000507638","article-title":"A rational use of clozapine based on adverse drug reactions, pharmacokinetics, and clinical pharmacopsychology","volume":"89","author":"de Leon J","year":"2020","unstructured":"de Leon J, Ruan CJ, Schoretsanitis G, De Las Cuevas C. A rational use of clozapine based on adverse drug reactions, pharmacokinetics, and clinical pharmacopsychology. Psychother Psychosom. 2020, 89:200-14. 10.1159\/000507638","journal-title":"Psychother Psychosom"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e31817ea9c1","article-title":"Neuroleptic malignant syndrome and the acute phase response","volume":"28","author":"Rosebush PI","year":"2008","unstructured":"Rosebush PI, Anglin RE, Richards C, Mazurek MF. Neuroleptic malignant syndrome and the acute phase response. J Clin Psychopharmacol. 2008, 28:459-61. 10.1097\/JCP.0b013e31817ea9c1","journal-title":"J Clin Psychopharmacol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/507497-atypical-neuroleptic-malignant-syndrome-without-rigidity-during-clozapine-titration-a-diagnostic-challenge","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T22:14:38Z","timestamp":1784758478000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/507497-atypical-neuroleptic-malignant-syndrome-without-rigidity-during-clozapine-titration-a-diagnostic-challenge"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.113175","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,22]]}}}